Richard A Scolyer Selected Research

Cadherins (E-Cadherin)

5/2013	Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion.
12/2012	E-cadherin expression in the epithelial components of mammary phyllodes tumors.
4/2003	Increased expression of apoptotic markers in melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard A Scolyer Research Topics

Disease

278	Melanoma (Melanoma, Malignant) 05/2024 - 08/2002
158	Neoplasms (Cancer) 04/2024 - 08/2002
65	Neoplasm Metastasis (Metastasis) 03/2024 - 10/2003
12	Nevus (Nevi) 04/2022 - 08/2002
10	Lymphatic Metastasis 04/2022 - 04/2004
8	Skin Neoplasms (Skin Cancer) 10/2023 - 02/2012
8	Brain Neoplasms (Brain Tumor) 01/2023 - 05/2015
7	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2015 - 01/2004
7	Phyllodes Tumor (Cystosarcoma Phylloides) 12/2012 - 07/2002
6	Uveal melanoma 12/2023 - 02/2014
6	Disease Progression 12/2022 - 01/2010
5	Neoplasm Micrometastasis 12/2022 - 07/2004
5	Margins of Excision 01/2019 - 04/2006
4	Extranodal Extension 12/2022 - 04/2012
4	Tonsillar Neoplasms 11/2016 - 09/2003
4	Carcinogenesis 05/2015 - 02/2012
3	Squamous Cell Carcinoma of Head and Neck 10/2023 - 10/2016
3	Basal Cell Carcinoma (Rodent Ulcer) 03/2023 - 05/2013
3	Colitis 11/2022 - 01/2019
3	Lung Neoplasms (Lung Cancer) 03/2022 - 01/2022
3	Breast Neoplasms (Breast Cancer) 01/2022 - 05/2009
3	Neuroblastoma 11/2017 - 02/2012
2	Actinic Keratosis 03/2023 - 10/2015
2	Inflammation (Inflammations) 01/2023 - 01/2017
2	Hypoxia (Hypoxemia) 01/2023 - 04/2014
2	Hypothyroidism 01/2022 - 01/2021
2	Thyrotoxicosis 01/2022 - 01/2021
2	Pneumonia (Pneumonitis) 01/2022 - 05/2004

Drug/Important Bio-Agent (IBA)

45	Biomarkers (Surrogate Marker)IBA 12/2023 - 09/2003
39	Immune Checkpoint InhibitorsIBA 04/2024 - 02/2015
34	Proteins (Proteins, Gene)FDA Link 12/2023 - 07/2002
26	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 08/2002
22	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2022 - 03/2014
17	ParaffinIBA 01/2023 - 02/2004
14	IpilimumabIBA 10/2023 - 12/2015
13	LigandsIBA 10/2023 - 12/2004
13	AntigensIBA 01/2023 - 05/2004
13	Formaldehyde (Formol)FDA Link 01/2023 - 12/2004
11	pembrolizumabIBA 03/2024 - 12/2015
11	NivolumabIBA 02/2024 - 12/2015
10	dabrafenibIBA 05/2024 - 03/2012
10	RNA (Ribonucleic Acid)IBA 04/2024 - 01/2020
10	MicroRNAs (MicroRNA)IBA 01/2023 - 09/2011
10	Phosphotransferases (Kinase)IBA 11/2017 - 08/2006
8	trametinibIBA 05/2024 - 12/2014
8	Eosine Yellowish-(YS) (Eosin)IBA 04/2024 - 09/2003
8	AntibodiesIBA 01/2022 - 06/2010
8	VemurafenibIBA 12/2015 - 03/2012
7	Circulating Tumor DNAIBA 01/2022 - 12/2015
7	Messenger RNA (mRNA)IBA 12/2021 - 09/2003
6	Hematoxylin (Haematoxylon)IBA 04/2024 - 09/2003
6	Cyclin D1IBA 10/2009 - 09/2003
5	ChemokinesIBA 01/2023 - 02/2008
5	CytokinesIBA 01/2023 - 03/2014
5	EnzymesIBA 01/2019 - 09/2012
5	Cyclin-Dependent Kinase Inhibitor p16IBA 11/2011 - 09/2003
5	Protons (Proton)IBA 08/2010 - 06/2003
4	Niacinamide (Nicotinamide)FDA LinkGeneric 03/2023 - 10/2015
4	5-hydroxymethylcytosineIBA 12/2022 - 09/2012
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 01/2010
4	ChromatinIBA 01/2021 - 08/2002
4	Transcription Factors (Transcription Factor)IBA 01/2019 - 03/2012
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2017 - 03/2014
4	Capsules (Microcapsules)IBA 04/2012 - 07/2004
4	Cell Cycle ProteinsIBA 10/2009 - 09/2003
4	AntimonyIBA 05/2008 - 03/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2024 - 10/2006
3	InterferonsIBA 01/2024 - 01/2019
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2022 - 07/2004
3	MART-1 AntigenIBA 12/2021 - 09/2015
3	SuspensionsIBA 01/2021 - 06/2010
3	Histone Deacetylases (Histone Deacetylase)IBA 01/2018 - 01/2013
3	CateninsIBA 12/2017 - 01/2014
3	Mitogen-Activated Protein KinasesIBA 11/2017 - 04/2014
3	B7-H1 AntigenIBA 11/2017 - 07/2016
3	Adenosine (Adenocard)FDA LinkGeneric 01/2017 - 12/2009
3	Glucose (Dextrose)FDA LinkGeneric 07/2015 - 03/2009
3	Cadherins (E-Cadherin)IBA 05/2013 - 04/2003
2	SteroidsIBA 05/2024 - 11/2020
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2023 - 09/2004
2	Programmed Cell Death 1 ReceptorIBA 10/2023 - 11/2020
2	Antineoplastic Agents (Antineoplastics)IBA 10/2023 - 01/2018
2	ErbB Receptors (EGF Receptor)IBA 08/2023 - 04/2009
2	CarbonIBA 01/2023 - 05/2008
2	Differentiation AntigensIBA 01/2023 - 12/2020
2	NucleotidesIBA 01/2023 - 12/2015
2	GTP-Binding Proteins (G-Protein)IBA 12/2022 - 02/2012
2	Apoptosis Regulatory ProteinsIBA 01/2022 - 01/2010
2	Imiquimod (Aldara)FDA LinkGeneric 01/2022 - 11/2021

Therapy/Procedure

112	Therapeutics 05/2024 - 05/2004
73	Immunotherapy 04/2024 - 09/2012
31	Lymph Node Excision (Lymph Node Dissection) 05/2024 - 07/2004
11	Neoadjuvant Therapy 05/2024 - 01/2019
9	Radiotherapy 10/2023 - 06/2007
8	Drug Therapy (Chemotherapy) 08/2023 - 01/2017
6	Precision Medicine 07/2022 - 12/2012
5	Adjuvant Radiotherapy 11/2017 - 09/2008
4	Chemoprevention 03/2023 - 10/2015
4	Aftercare (After-Treatment) 05/2022 - 03/2012
3	Molecular Targeted Therapy 01/2020 - 01/2008